This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Destiny Pharma Valuation

Is D89 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of D89 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate D89's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate D89's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for D89?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for D89. This is calculated by dividing D89's market cap by their current preferred multiple.
What is D89's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	UK£3.90m

D89 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	n/a
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does D89's PS Ratio compare to its peers?

The above table shows the PS ratio for D89 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	3.2x
CNW co.don	0.7x	n/a	€6.5m
PA8 Paion	0.2x	30.2%	€2.6m
2INV 2invest	7.8x	n/a	€60.4m
MDG1 Medigene	4.2x	16.1%	€31.2m
D89 Destiny Pharma	4.7x	-171.4%	€4.5m

Price-To-Sales vs Peers: D89 is good value based on its Price-To-Sales Ratio (3.5x) compared to the peer average (4x).

Price to Earnings Ratio vs Industry

How does D89's PE Ratio compare vs other companies in the DE Biotechs Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	35.6%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	35.6%
	n/a	n/a	n/a

No more companies

Price-To-Sales vs Industry: D89 is good value based on its Price-To-Sales Ratio (3.5x) compared to the European Biotechs industry average (9.3x).

Price to Sales Ratio vs Fair Ratio

What is D89's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

D89 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	4.7x
Fair PS Ratio	0.002x

Price-To-Sales vs Fair Ratio: D89 is expensive based on its Price-To-Sales Ratio (3.5x) compared to the estimated Fair Price-To-Sales Ratio (0x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.